GILEAD TO ACQUIRE MYOGEN FOR $2.5 BILLION

Gilead Sciences Inc., the world's third-biggest biotechnology company, said on Monday it agreed to acquire Myogen Inc. for $2.5 billion in a surprise transaction that gives Gilead access to Myogen's experimental hypertension drugs. MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=OBR&Date=20061002&ID=6067386)